Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Events

<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>

How SMEs succeed in a risk averse market and win in China (free)

Start: Feb 27, 2014 5:00:00 PM

In this case study, we will summarise our approach. This will cover the three key bases of: securing funding, working in Emergent Markets and addressing the development requirements.
<< 2013 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2015 >>